中华眼科杂志
中華眼科雜誌
중화안과잡지
Chinese Journal of Ophthalmology
2015年
10期
730-733
,共4页
角膜新生血管化%血管生成抑制剂%抗体,单克隆,人%评价研究
角膜新生血管化%血管生成抑製劑%抗體,單剋隆,人%評價研究
각막신생혈관화%혈관생성억제제%항체,단극륭,인%평개연구
Corneal neovascularization%Angiogenesis inhibitors%Antibodies,monoclonal,humanized%Evaluation studies
在治疗角膜新生血管方面,以雷珠单抗和贝伐单抗为代表的新型抗VEGF药物的临床应用及研究均取得重大突破,而二者的有效性及安全性比较是当前临床争议的焦点.虽然部分实验结果表明贝伐单抗的药效优于雷珠单抗,但是雷珠单抗具有起效时间短、对VEGF-A的亲和力强、重复注射时耐受性好等优点.结合实验研究结果,我们认为充足剂量的雷珠单抗效果更优,其临床应用应引起广泛重视.
在治療角膜新生血管方麵,以雷珠單抗和貝伐單抗為代錶的新型抗VEGF藥物的臨床應用及研究均取得重大突破,而二者的有效性及安全性比較是噹前臨床爭議的焦點.雖然部分實驗結果錶明貝伐單抗的藥效優于雷珠單抗,但是雷珠單抗具有起效時間短、對VEGF-A的親和力彊、重複註射時耐受性好等優點.結閤實驗研究結果,我們認為充足劑量的雷珠單抗效果更優,其臨床應用應引起廣汎重視.
재치료각막신생혈관방면,이뢰주단항화패벌단항위대표적신형항VEGF약물적림상응용급연구균취득중대돌파,이이자적유효성급안전성비교시당전림상쟁의적초점.수연부분실험결과표명패벌단항적약효우우뢰주단항,단시뢰주단항구유기효시간단、대VEGF-A적친화력강、중복주사시내수성호등우점.결합실험연구결과,아문인위충족제량적뢰주단항효과경우,기림상응용응인기엄범중시.
The studies and clinical applications of Ranibizumab and Bevacizumab which are new anti-VEGF drugs have made significant progression on the treatment of corneal neovascularization.The effectiveness and safety of Ranibizumab compared with Bevacizumab has been the focus of the debate for scholars nowadays.Some experiments showed that the effect of Bevacizumab was better than Ranibizumab.But combined with our experiments, Ranibizumab represented the advantages of shorter effect time, stronger affinity with VEGF-A, better tolerance with repeated injections etc.So we believed that the adequate doses of ranibizumab had better effects.Its clinical application should be paid much attention.
